Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bataille, R
Right arrow Articles by Moreau, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bataille, R
Right arrow Articles by Moreau, P
Haematologica, Vol 90, Issue 5, 706-707
Copyright © 2005 by Ferrata Storti Foundation

Letter

CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity

R Bataille, N Robillard, H Avet-Loiseau, JL Harousseau, and P Moreau

We investigated the expression of insulin-like growth factor-1 receptor (CD221) in normal, reactive and malignant plasma cells. We show that CD221 is aberrantly expressed on human myeloma cells, that higher levels of CD221 are observed in patients and human myeloma cell lines with the most aggressive 14q32 translocations, and that CD221 expression has a negative prognostic impact in patients with multiple myeloma.


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
B. M. Birmann, R. M. Tamimi, E. Giovannucci, B. Rosner, D. J. Hunter, P. Kraft, C. Mitsiades, K. C. Anderson, and G. A. Colditz
Insulin-like Growth Factor-1- and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma
Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 282 - 288.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Q. Lacy, M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, et al.
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
J. Clin. Oncol., July 1, 2008; 26(19): 3196 - 3203.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.